- Home
- PGZ vs KRON Comparison
PGZ vs KRON Comparison
Compare PGZ & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGZ
- KRON
- Stock Information
- Founded
- PGZ 2012
- KRON 2017
- Country
- PGZ United States
- KRON United States
- Employees
- PGZ N/A
- KRON N/A
- Industry
- PGZ Investment Managers
- KRON Medicinal Chemicals and Botanical Products
- Sector
- PGZ Finance
- KRON Health Care
- Exchange
- PGZ Nasdaq
- KRON Nasdaq
- Market Cap
- PGZ 68.3M
- KRON 59.8M
- IPO Year
- PGZ N/A
- KRON 2020
- Fundamental
- Price
- PGZ $10.25
- KRON $0.99
- Analyst Decision
- PGZ
- KRON Buy
- Analyst Count
- PGZ 0
- KRON 3
- Target Price
- PGZ N/A
- KRON $1.63
- AVG Volume (30 Days)
- PGZ 23.0K
- KRON 292.4K
- Earning Date
- PGZ 01-01-0001
- KRON 11-13-2024
- Dividend Yield
- PGZ 12.26%
- KRON N/A
- EPS Growth
- PGZ N/A
- KRON N/A
- EPS
- PGZ N/A
- KRON N/A
- Revenue
- PGZ N/A
- KRON $9,864,000.00
- Revenue This Year
- PGZ N/A
- KRON $62.21
- Revenue Next Year
- PGZ N/A
- KRON N/A
- P/E Ratio
- PGZ N/A
- KRON N/A
- Revenue Growth
- PGZ N/A
- KRON 146.48
- 52 Week Low
- PGZ $8.46
- KRON $0.69
- 52 Week High
- PGZ $10.59
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- PGZ 53.77
- KRON 53.61
- Support Level
- PGZ $10.11
- KRON $0.92
- Resistance Level
- PGZ $10.14
- KRON $1.02
- Average True Range (ATR)
- PGZ 0.12
- KRON 0.05
- MACD
- PGZ 0.07
- KRON 0.00
- Stochastic Oscillator
- PGZ 87.93
- KRON 70.05
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.